These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 29991320

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
    Frandsen CS, Dejgaard TF, Madsbad S.
    Lancet Diabetes Endocrinol; 2016 Sep; 4(9):766-780. PubMed ID: 26969516
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J.
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
    DeGeeter M, Williamson B.
    J Pharm Pract; 2016 Apr; 29(2):144-59. PubMed ID: 25312263
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological management of type 2 diabetes mellitus: an update.
    El-Kaissi S, Sherbeeni S.
    Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
    Elian V, Popovici V, Karampelas O, Pircalabioru GG, Radulian G, Musat M.
    Int J Mol Sci; 2024 Feb 06; 25(4):. PubMed ID: 38396657
    [Abstract] [Full Text] [Related]

  • 12. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M, Shibasaki M, Echizen H, Kushiyama A.
    PLoS One; 2020 Feb 06; 15(7):e0236603. PubMed ID: 32706828
    [Abstract] [Full Text] [Related]

  • 13. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec 06; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL, Davis TME.
    Clin Ther; 2017 May 06; 39(5):1012-1025. PubMed ID: 27863704
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD, Gershman JA.
    Adv Ther; 2013 Apr 06; 30(4):337-53. PubMed ID: 23605247
    [Abstract] [Full Text] [Related]

  • 18. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
    Hermansen K, Mortensen LS.
    Drug Saf; 2007 Apr 06; 30(12):1127-42. PubMed ID: 18035865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes.
    Tosur M, Redondo MJ, Lyons SK.
    Curr Diab Rep; 2018 Aug 17; 18(10):79. PubMed ID: 30116997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.